Lucid Diagnostics vs Beyond Air
Beyond Air reported revenue of $8 million in fiscal 2026, 1.6 times Lucid Diagnostics' $5 million in fiscal 2025. Lucid Diagnostics' revenue grew 8.3% in its latest year, and Beyond Air's grew 107.3%. Lucid Diagnostics had an operating margin of -1054.8%, against -378.2% at Beyond Air. Free cash flow was −$47 million at Lucid Diagnostics and −$19 million at Beyond Air. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.
Side by side
| Lucid Diagnostics | Beyond Air | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Mar 31, 2026 |
| Revenue | $5M | $8M |
| Revenue growth | 8.3% | 107.3% |
| Revenue growth a year, last 5 years | — | 53.6% |
| Gross margin | −41.7% | 3.3% |
| Operating margin | −1,054.8% | −378.2% |
| Net margin | −1,232.7% | −433.0% |
| Free cash flow | −$47M | −$19M |
| Free cash flow margin | −992.0% | −249.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 101.8% | 145.2% |
| Last close | $0.39 | $1.72 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $245,000, sold $0 | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Lucid DiagnosticsBeyond Air
Operating margin
Percent of revenue
Lucid DiagnosticsBeyond Air
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Lucid DiagnosticsBeyond Air
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Lucid Diagnostics and Beyond Air pages.